CART19 cell therapy for lupus in young people
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 29 years old.
- You must have lupus that is active and hasn't improved after at least 3 months of standard treatments like mycophenolate mofetil or cyclophosphamide, plus one other medicine (like rituximab or belimumab).
- You need to have had a positive ANA blood test (titer >1:80) or positive double-stranded DNA test.
- If you have kidney lupus, a recent biopsy must show active disease and high protein in your urine.
- If you don't have kidney lupus, your lupus must still be active (measured by a disease score) or you cannot lower your prednisone dose because of active disease.
- Your organs (kidneys, liver, heart, lungs) must work well enough – for example, no dialysis, no severe liver damage, and no severe breathing problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
This early-phase trial tests a special immune cell therapy (CAR-T) for people with lupus nephritis that has not improved with standard treatments. The therapy uses your own modified cells to target and calm the overactive immune system causing kidney damage.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.